KRAS
PulseAugur coverage of KRAS — every cluster mentioning KRAS across labs, papers, and developer communities, ranked by signal.
3 day(s) with sentiment data
-
FDA approves new pancreatic cancer drug daraxonrasib after trial success
The U.S. FDA has approved daraxonrasib (Rasonque), a new targeted therapy for pancreatic ductal adenocarcinoma (PDAC) in adults whose disease has spread and failed other treatments. This marks a significant advancement …
-
New antibodies target previously inaccessible KRAS cancer mutations
Researchers have developed a novel antibody-based therapy that targets a common weakness in cancer cells, specifically mutations in the KRAS protein. This new approach leverages the cell's natural surface display system…
-
AI predicts lung cancer mutations from scans using multi-label learning
Researchers have developed a multi-label learning approach using deep learning to predict specific gene mutations (EGFR, TP53, and KRAS) in non-small cell lung cancer (NSCLC) from PET/CT scans. The study, conducted on a…
-
New drug Setidegrasib destroys cancer-driving KRAS protein
A new drug, Setidegrasib, is showing promise in destroying the KRAS protein, a common driver in difficult cancers like pancreatic, colorectal, and lung cancers. Unlike traditional drugs that merely block the KRAS protei…
-
RAS-targeted therapies show promise for new cancer treatments
CITIC Securities has released a research report highlighting the potential of RAS-targeted therapies in oncology. These therapies aim to unlock previously undruggable targets within the RAS gene family, which includes K…
-
New scBench-Long benchmark tests AI in complex single-cell biology analysis
Researchers have introduced scBench-Long, a new benchmark designed to evaluate AI agents' capabilities in complex, multi-step single-cell biology analysis. Unlike previous benchmarks that focused on broad knowledge or l…
-
New antibody treatment targets hard-to-reach pancreatic cancer protein
Researchers have developed a novel experimental treatment for pancreatic cancer that targets a difficult-to-reach protein deep within cells. This new approach uses carrier particles to deliver antibodies inside the cell…
-
Neuro-Symbolic Framework Enhances Colorectal Cancer Drug Response Insights
Researchers have developed a novel neuro-symbolic framework called the Contextual Invertible World Model (CIWM) to address limitations in precision oncology. This framework integrates a machine learning emulator with a …
-
Daraxonrasib doubles survival for pancreatic cancer patients
Daraxonrasib, a new drug developed by Revolution Medicines, has shown significant promise in treating pancreatic ductal adenocarcinoma, a notoriously deadly cancer. In a Phase 3 trial, the drug doubled survival duration…
-
New benchmark ShallowBench targets AI drug design for shallow pockets
Researchers have developed ShallowBench, a new benchmark designed to evaluate generative AI models used in drug design, specifically focusing on targets with shallow binding pockets. Existing models perform poorly on th…
-
New framework tackles complex knowledge graph queries with multiple variables
Researchers have developed a new framework called Neural Scalable Symbolic Search (NS3) to address the challenge of complex query answering over knowledge graphs. Existing methods struggle with queries involving multipl…